Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 3/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972143 | 0.85 | PTPN7 (0.56) | MCHR1AURKAAURKBBRD4LRRK2 | |
| SCHEMBL9964598 | 0.84 | BRD4 (0.55) | CNR2IGF1RMCHR1AURKAAURKB | |
| SCHEMBL15082471 | 0.83 | AURKA (0.57) | PTK2IGF1RAURKAAURKBBRD4 | |
| SCHEMBL738237 | 0.83 | HTR4 (0.53) | PTK2MCHR1AURKAAURKBBRD4 | |
| SCHEMBL410671 | 0.83 | AURKA (0.52) | PTK2IGF1RMCHR1AURKAAURKB | |
| SCHEMBL22280231 | 0.81 | LRRK2 (0.55) | PTK2IGF1RHTR7AURKAAURKB | |
| SCHEMBL19651825 | 0.80 | KMT2A (0.56) | CNR2CYP2D6CYP2C9 | |
| SCHEMBL19651858 | 0.80 | CYP2D6 (0.57) | CNR2MCHR1CYP2D6CYP2C9 | |
| SCHEMBL13880647 | 0.80 | AURKA (0.52) | PTK2MCHR1AURKAAURKBBRD4 | |
| SCHEMBL19651836 | 0.80 | MAPK14 (0.53) | CNR2MCHR1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | PTK2 270/4885CNR2 1556/4885IGF1R 2798/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | PTK2 270/4885CNR2 1556/4885IGF1R 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.